Breaking News

Replimune Group initiated with an Outperform at Leerink. Leerink analyst Jonathan Chang started Replimune Group with an Outperform rating and $25 price target. While the company is still in the early stages of clinical development, the analyst has a positive long-term view on the stock because of Replimune Group's experienced management team, clear clinical strategy moving into combination trials, and potential broad applicability to injectable tumors. Chang also believes that it has a lower risk profile when compared to other oncolytic virus companies.

Replimune Group initiated with an Outperform at BMO Capital. As reported earlier, BMO Capital analyst Do Kim initiated Replimune with an Outperform rating and a price target of $31, saying its platform has been "significantly de-risked" based on its "structural similarity to T-Vec, the only FDA-approved oncolytic virus." The analyst contends that Replimune's RP1 is better than T-Vec, with a " more potent HSV-1 strain and addition of fusogenic protein GALV", and can deliver on rising expectations for oncolytic viruses helped by the advent of immunotherapy.

Replimune Group initiated with an Outperform at BMO Capital

Replimune Group initiated with an Overweight at JPMorgan. JPMorgan analyst Anupam Rama started Replimune Group with an Overweight rating and $26 price target. Replimune is an emerging oncolytic immunotherapy platform company that has "multiple de-risking points," Rama tells investors in a research note.